In the IMPACT trial, pemvidutide achieved mean weight losses of 4.8% and 5.8% with 1.2 and 1.8 mg doses respectively at 24 weeks, compared to 0.5% with placebo, with weight loss curves showing no evidence of plateauing, suggesting continued benefit with longer treatment [49-51]
GLP-1 receptor agonists are medications originally developed for Type 2 diabetes that work by mimicking a natural hormone in your body to regulate blood sugar, slow digestion, and reduce appetite
doi: 10.1111/dom.14551
Thats why working closely with us and reporting any unusual symptoms is so important
But I do wanna talk about potential brain and heart health benefits as well that we're starting to see in the research, because I think, okay, so weight loss is important in some instances, but I think these drugs are also showing benefit for both brain and heart health, and we should be [00:16:00] considering that as well in menopause therapy
Am J Physiol Heart Circ Physiol